RecruitingPhase 2NCT03392233

Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors

A Phase II Study to Evaluated the Long-term of Safety and Efficacy of Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors

Sponsor

RenJi Hospital

Enrollment

100 participants

Start Date

Aug 18, 2017

Study Type

INTERVENTIONAL

Conditions

Breast Cancer Prostate Cancer Non-small Cell Lung Cancer

Summary

Stereotactic Body Radiation Therapy(SBRT) for spinal metastases has been proved a good results in pain relieve and local control, However,the longterm of efficacy and safety of this regimen is unclear.The purpose of the study is to evaluate the longterm outcome of this therapeutic regimen in selective patients who will be survival more than 2 years.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This trial is evaluating stereotactic body radiation therapy (SBRT) — a highly precise, high-dose form of targeted radiation — for treating painful cancer that has spread to the spine (spinal metastases), to see if it can provide better and longer-lasting pain relief than standard radiation. **You may be eligible if...** - Your cancer has been confirmed by tissue or cell testing - You have cancer that has spread to the spine, confirmed by imaging (CT, MRI, or PET-CT scan) - The spinal metastases affect no more than 3 consecutive vertebrae (bones in the spine) - You have a baseline pain score of 5 or more out of 10 - You are in reasonably good overall health (WHO performance score 0 to 2) - Your bone marrow, liver, and kidney function meet the required levels **You may NOT be eligible if...** - Cancer has spread to more than 3 consecutive vertebrae at the target site - Your pain score is below 5 before treatment - Your organ function is too poor to receive radiation therapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONStereotactic Body Radiation Therapy

Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time

Locations(1)

Department of Radiation Oncology,Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03392233

Related Trials

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386312 locations

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

NCT068144962 locations

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

NCT0679763517 locations

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

NCT070764854 locations

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

NCT0553813081 locations